drugset / Trial / NCT01304277
This Study is Designed to Evaluate PD/PK and Safety of Replagal Manufactured by Two Different Processes.
NaSingle-groupOpen-labelOther
Summary
This study is designed to evaluate safety and PK/PD in Canadian Fabry patients.
Timeline
- Start
- 2011-11-17
- Primary completion
- 2012-12-28
- Completion
- 2012-12-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Replagal | Protein / enzyme biologic | 0.2 mg/kg | Intravenous |